Genomics Core

摘要 一个严重的缺口往往存在于为服务不足、健康差距人群和代表性不足的人群提供服务的机构 学生(ISUP)在获得基因组技术和与所需的高成本相关的成本之间 仪器、技术熟练程度和分析专业知识。基因组学核心(GC)解决了这一差距 通过以更低的费用提供专家和负担得起的高通量基因组学技术 所有合伙企业调查员。GC通过提供创新的方法使整个合作伙伴关系受益 探索早期的项目想法，并通过与合作伙伴调查人员及其受训人员合作来促进使用 利用基因组学技术建立可持续的癌症生物学和癌症差异研究。要完成 这些目标，GC(通过个性化癌症治疗中心的赞助，CPCT)提供 为伙伴关系提供一线基因组学相关技术以及数据分析的生物信息学支持 调查人员通过负担得起的报销模式。GC建议实现这些目标 通过追求四个具体目标，旨在建设生物医学和癌症研究以及 通过弥补基于基因组学的尖端工具的可获得性差距，在波士顿大学进行培训；支持 希望寻求早期项目想法的伙伴关系调查员，特别是那些需要创新的项目 和/或在技术上具有挑战性的基因组学方法；弥合学生和高层之间的培训差距 以基因组学为基础的技术，并提供核心产生的数据的生物信息学分析。在这 应用，GC专门支持FP2：针对男性前列腺癌的雄激素受体信号转导 非洲血统-Steven Balk(DF/HCC-BIDMC)和Changmeng Cai(华盛顿大学波士顿分校)和PP2：High BRCA2缺陷的非裔美国人前列腺癌中CHD1缺失的频率导致治疗耐药性- Zoltan Szallasi(DF/HCC-BCH)和Shailja Pathania(UMassBoston)。

SUMMARY A critical gap often exists at institutions serving underserved health disparity populations and underrepresented students (ISUPS) between access to Genomics technologies and the high costs associated with the required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology and cancer disparities research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core. In this application, the GC specifically supports FP2: Targeting androgen receptor signaling in prostate cancer in men with African Ancestry – Steven Balk (DF/HCC - BIDMC) and Changmeng Cai (UMass Boston) and PP2: High frequency of CHD1 loss in BRCA2-deficient African American prostate tumors drives treatment resistance – Zoltan Szallasi (DF/HCC - BCH) and Shailja Pathania (UMass Boston).